Adherence to surgical and oncologic standards improves survival in breast cancer patients
- 6 June 2019
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 120 (2) , 148-159
Abstract
Background: Adherence to evidence‐based standards can lead to improved outcomes for patients with breast cancer. However, adherence rates to standards and their effects on patient outcomes are unknown.Objectives: To examine adherence rates to standards compiled by the American College of Surgeons Clinical Research Program and its effects on patient outcomes.Methods: Using the National Cancer Database (2004‐2015), we identified cohorts of breast cancer patients: clinical T1N0M0 under age of 70 (cT1), clinical T2N0M0 or T3N0M0 (cT2/3), and clinical M0 and pathologic N2 or N3 (pN2/3). Standards included negative margins, any adjuvant therapy, and two or more lymph nodes (LNs) examined (for cT1 or cT2/3 patients) or more than 10 LNs examined (for pN2/3 patients). We performed Kaplan‐Meier and Cox proportional hazards analysis.Results: We identified 318 853 (65.0%) cT1, 164 593 (67.3%) cT2/3, and 77 626 (67.7%) pN2/3 patients who met the standards. More than 90% of patients had negative margins and adjuvant therapy, but less than 80% met LN standards. The median overall survival (OS) was significantly longer for patients who met the standards. Individual components of the standards were predictors of improved OS.Conclusions: One‐third of patients did not meet the evidence‐based standards in their treatment for breast cancer. Efforts to improve the knowledge of and adherence to these standards should be emphasized.Keywords
Funding Information
- U.S. National Library of Medicine (T15LM011271)
This publication has 26 references indexed in Scilit:
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast CancerJAMA, 2013
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival—a retrospective multi-centre cohort studyBreast Cancer Research and Treatment, 2011
- Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast‐conservation therapy for lymph node‐negative, human epidermal growth factor receptor 2‐positive breast cancerCancer, 2011
- Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node MetastasisJAMA, 2011
- How Many Sentinel Lymph Nodes Are Enough for Accurate Axillary Staging in T1-2 Breast Cancer?Journal of Breast Cancer, 2011
- How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?Cancer, 2008
- Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trialThe Lancet Oncology, 2007
- Sentinel lymph node biopsy for breast cancer: How many nodes are enough?Journal of Surgical Oncology, 2007
- Compliance With Consensus Recommendations for Systemic Therapy Is Associated With Improved Survival of Women With Node-Negative Breast CancerJournal of Clinical Oncology, 2004